TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that its
subsidiary, Xyphos Biosciences Inc, and Poseida Therapeutics Inc. (PSTX) have
entered into a research collaboration and license agreement to develop novel
convertibleCAR programs by combining the innovative cell therapy platforms from
each of the companies.

As per the terms of the agreement, the companies plan to combine Poseida's
proprietary allogeneic CAR-T platform with Xyphos' ACCEL technology to create
one Poseida-developed CAR-T construct to form the basis of two convertibleCAR
product candidates targeting solid tumors.

Xyphos will reimburse Poseida for costs incurred as part of the research
agreement and will be responsible for the development and future
commercialization of products generated from the collaboration.

Poseida will receive US$50 million upfront plus potential development and sales
milestones and contingency payments of up to US$550 million in total.
Additionally, Poseida is eligible for up to low double digit tiered royalties as
a percentage of net sales.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX